Sanofi (NASDAQ:SNY – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, January 30th. Analysts expect Sanofi to post earnings of $0.70 per share and revenue of $10.57 billion for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Sanofi Trading Down 0.7 %
Shares of SNY stock opened at $52.97 on Wednesday. The firm has a 50 day moving average price of $48.90 and a two-hundred day moving average price of $52.22. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $134.43 billion, a PE ratio of 27.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.
Analyst Ratings Changes
Separately, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
- Five stocks we like better than Sanofi
- Canada Bond Market Holiday: How to Invest and Trade
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Are Penny Stocks a Good Fit for Your Portfolio?
- What Does the Future Hold for Eli Lilly?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.